130985-42-1

Usage

Uses

Used in Pharmaceutical Development:
Ethyl 3-(tert-butoxycarbonylamino)-3-methylbutanoate is used as a key intermediate in the synthesis of peptides and proteins for the development of new pharmaceuticals. The Boc protecting group allows for the controlled formation of peptide bonds, while the ethyl ester group aids in the solubility and reactivity of the compound, making it easier to incorporate into complex molecular structures.
Used in Bioactive Molecule Synthesis:
In the field of bioactive molecule synthesis, Ethyl 3-(tert-butoxycarbonylamino)-3-methylbutanoate is utilized as a versatile building block. Its structural features enable the creation of a wide range of bioactive compounds with potential applications in medicine and biotechnology.
Used in Protein Structure and Function Studies:
Ethyl 3-(tert-butoxycarbonylamino)-3-methylbutanoate is employed as a component in the study of protein structure and function. Its ability to be selectively manipulated during synthesis allows researchers to probe the effects of specific amino acid modifications on protein behavior, contributing to a deeper understanding of protein dynamics and interactions.
Used in Organic Synthesis Industry:
Ethyl 3-(tert-butoxycarbonylamino)-3-methylbutanoate is used as a valuable building block in the organic synthesis industry. Its unique properties, including the Boc protecting group and ethyl ester functionality, make it a preferred choice for the synthesis of complex organic molecules with specific biological activities or structural features.

Upstream product

• 638-10-8 ethyl 3-methylbut-2-enoate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 85532-40-7 Ethyl 3-amino-3-methylbutanoate hydrochloride salt 
• 85532-42-9 ethyl 3-amino-3-methylbutanoate 

Downstream Products

• 130985-44-3 N-α--L-phenylalanyl>-N^α-methyl-N^im-tosyl-L-histydyl>-5(S)-amino-6-cyclohexyl-4(S)-hydroxy-2(S)-isopropylhexanoyl>-L-isoleucyl>-2-pyridylmethylamine 
• 130985-46-5 N-α--L-phenylalanyl>-N^α-methyl-L-histidyl>-5(S)-amino-6-cyclohexyl-4(S)-hydroxy-2(S)-isopropylhexanoyl>-L-isoleucyl>(1-oxo-2-pyridyl)methylamine 
• 130985-45-4 N-α--L-phenylalanyl>-N^α-methyl-L-histydyl>-5(S)-amino-6-cyclohexyl-4(S)-hydroxy-2(S)-isopropylhexanoyl>-L-isoleucyl>-2-pyridylmethylamine 
• 135378-86-8 C₅₃H₈₁N₇O₉S 
• 135378-87-9 [2-((S)-1-{[(S)-1-[(1S,2S,4S)-1-Cyclohexylmethyl-2-hydroxy-5-methyl-4-((S)-2-methyl-butylcarbamoyl)-hexylcarbamoyl]-2-(1H-imidazol-4-yl)-ethyl]-methyl-carbamoyl}-2-phenyl-ethylcarbamoyl)-1,1-dimethyl-ethyl]-carbamic acid tert-butyl ester 
• 135378-56-2 (2S,4S,5S)-5-[(S)-2-{[(S)-2-(3-Amino-3-methyl-butyrylamino)-3-phenyl-propionyl]-methyl-amino}-3-(1H-imidazol-4-yl)-propionylamino]-6-cyclohexyl-4-hydroxy-2-isopropyl-hexanoic acid ((S)-2-methyl-butyl)-amide 
• 130985-58-9 N-α-(β-L-valyl)-L-phenylalanyl-N^α-methyl-L-histidyl>-5(S)-amino-6-cyclohexyl-4(S)-hydroxy-2(S)-isopropylhexanoyl>-L-isoleucyl>(1-oxo-2-pyridyl)methylamine tris(trifluoroacetate) 
• 130985-57-8 N-α-(β-L-valyl-L-phenylalanyl)-N^α-methyl-L-histydyl>-5(S)-amino-6-cyclohexyl-4(S)-hydroxy-2(S)-isopropylhexanoyl>-L-isoleucyl>-2-pyridylmethylamine tris(trifluoroacetate) 

Relevant academic research and scientific papers

AMINOPYRAZOLONE DERIVATIVE

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which has an excellent inhibitory action on the ATPase activity of a TIP48/TIP49 complex and as such, is useful for the treatment of tumors. [Solution] The present invention provides a compound having a structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the present specification.

BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2

The present invention relates to novel pyrimido[1,6-a]pyrimidin-6(2H)-one compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

Renin inhibitory peptides. Incorporation of polar, hydrophilic end groups into an active renin inhibitory peptide template and their evaluation in a human renin infused rat model and in conscious sodium-depleted monkeys

We previously reported that Boc-Pro-Phe-N-MeHis-Leuψ[CHOHCH2]-Ile-Amp (1) is a potent and specific inhibitor of human renin in vitro. It was shown to resist degradation by selected proteases and a rat liver homogenate. It was shown to inhibit p